• bitcoinBitcoin(BTC)$78,006.000.90%
  • ethereumEthereum(ETH)$2,270.571.09%
  • tetherTether(USDT)$1.000.01%
  • binancecoinBNB(BNB)$716.771.44%
  • rippleXRP(XRP)$1.250.38%
  • usd-coinUSDC(USDC)$1.000.00%
  • solanaSolana(SOL)$94.97-0.78%
  • tronTRON(TRX)$0.311569-0.99%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.084.70%
  • zcashZcash(ZEC)$1,240.09-2.75%
  • HyperliquidHyperliquid(HYPE)$87.911.26%
  • dogecoinDogecoin(DOGE)$0.0757470.35%
  • moneroMonero(XMR)$602.031.10%
  • USDSUSDS(USDS)$1.000.00%
  • chainlinkChainlink(LINK)$11.620.95%
  • whitebitWhiteBIT Coin(WBT)$74.900.92%
  • leo-tokenLEO Token(LEO)$9.380.05%
  • cardanoCardano(ADA)$0.1933250.24%
  • stellarStellar(XLM)$0.168431-1.05%
  • nearNEAR Protocol(NEAR)$4.37-1.34%
  • bitcoin-cashBitcoin Cash(BCH)$283.78-1.29%
  • uniswapUniswap(UNI)$7.304.06%
  • daiDai(DAI)$1.00-0.02%
  • Ethena USDeEthena USDe(USDE)$1.000.00%
  • RainRain(RAIN)$0.0062742.26%
  • litecoinLitecoin(LTC)$55.891.14%
  • CantonCanton(CC)$0.0980781.42%
  • avalanche-2Avalanche(AVAX)$8.783.36%
  • USD1USD1(USD1)$1.000.00%
  • suiSui(SUI)$0.900.18%
  • the-open-networkGram (prev. Toncoin)(GRAM)$1.231.64%
  • hedera-hashgraphHedera(HBAR)$0.071874-0.12%
  • tether-goldTether Gold(XAUT)$3,872.680.01%
  • Global DollarGlobal Dollar(USDG)$1.000.01%
  • quant-networkQuant(QNT)$198.30-0.87%
  • paypal-usdPayPal USD(PYUSD)$1.00-0.03%
  • shiba-inuShiba Inu(SHIB)$0.000005-0.16%
  • BittensorBittensor(TAO)$235.660.06%
  • crypto-com-chainCronos(CRO)$0.051657-0.25%
  • EthenaEthena(ENA)$0.186263-2.97%
  • Ripple USDRipple USD(RLUSD)$1.000.02%
  • Ondo US Dollar YieldOndo US Dollar Yield(USDY)$1.150.02%
  • okbOKB(OKB)$113.982.87%
  • Circle USYCCircle USYC(USYC)$1.140.00%
  • aaveAave(AAVE)$138.582.71%
  • pepePepe(PEPE)$0.000005-2.57%
  • BlackRock USD Institutional Digital Liquidity FundBlackRock USD Institutional Digital Liquidity Fund(BUIDL)$1.000.00%
  • OndoOndo(ONDO)$0.407947-0.35%
  • Pump.funPump.fun(PUMP)$0.0042382.16%
  • MemeCoreMemeCore(M)$0.84-8.45%
TradePoint.io
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop
No Result
View All Result
TradePoint.io
No Result
View All Result

J&J found liable for cancer in latest talc trial, ordered to pay $250K

February 13, 2026
in Business
Reading Time: 3 mins read
A A
J&J found liable for cancer in latest talc trial, ordered to pay 0K
ShareShareShareShareShare

A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to blame for her ovarian cancer, according to an attorney for plaintiffs in nationwide talc litigation against the company.

YOU MAY ALSO LIKE

Trump’s tariff craze has derailed the GOP’s hopes to maintain their authority after the 2026 midterms

West Coast favorite ice cream chain opens new Bay Area store

The jury in the Philadelphia Court of Common Pleas sided with family members of Gayle Emerson, who claimed that Johnson & Johnson knew for years its talc-based products were dangerous but failed to warn consumers, according to attorney Chris Tisi.

Jurors awarded Emerson’s family $50,000 in compensatory damages and $200,000 in punitive damages, said Tisi, who represents plaintiffs in separate federal court talc cases against Johnson & Johnson.

Jurors awarded a Pennsylvania woman’s family $50,000 in compensatory damages and $200,000 in punitive damages. REUTERS

Representatives for J&J and lawyers for Emerson’s family did not immediately respond to requests for comment.

Emerson, a Pennsylvania resident, sued in 2019 and died six months later at the age of 68, according to court records. Her son and daughter took over as the plaintiffs after she died of metastatic ovarian cancer, according to the lawsuit.

Emerson used J&J’s baby powder from 1969 until 2017, when she learned from a relative it was associated with an increased risk of ovarian cancer, according to her lawsuit. She had been diagnosed with the cancer two years earlier, the lawsuit said.

J&J is facing lawsuits in federal and state courts from more than 67,000 plaintiffs who have alleged that its talc-based products contained asbestos and caused ovarian and other cancers, according to court filings.

The company has said its products are safe, do not contain asbestos and do not cause cancer. J&J stopped selling talc-based baby powder in the US in 2020, switching to a cornstarch product.

J&J is facing lawsuits in federal and state courts from more than 67,000 plaintiffs who have alleged that its talc-based products contained asbestos and caused ovarian and other cancers. AFP via Getty Images

J&J has sought to resolve the litigation through bankruptcy, a proposal that has been rejected three times by federal courts, most recently in April of last year. The bankruptcies had put most ovarian cancer cases on hold.

The first ovarian cancer case to go to trial after the end of the bankruptcy-related pause resulted in a California jury awarding $40 million to two women in December.

There are several cases slated for trial in state courts in the coming months. There has yet to be a trial in federal court, where most of the claims have been consolidated, but that could change this year after a federal magistrate judge ruled in January that the plaintiffs in the federal litigation can present testimony from experts that links baby powder use with ovarian cancer. J&J has said it will appeal the ruling.

The company has said its products are safe, do not contain asbestos and do not cause cancer. J&J stopped selling talc-based baby powder in the US in 2020, switching to a cornstarch product. Getty Images

Product liability lawsuits, such as the J&J cases, rely on experts to establish that the product is capable of causing the alleged harm.

Before the bankruptcy attempts, J&J had a mixed record in talc trials, with verdicts as high as $4.69 billion. The company has won some trials outright and had other verdicts reduced on appeal.

The majority of lawsuits involve ovarian cancer claims. Cases alleging talc caused a rare and deadly cancer called mesothelioma make up a smaller portion of the claims J&J is facing. The company has previously settled some of those claims but has not struck a nationwide settlement, so many lawsuits over mesothelioma have proceeded to trial in state courts in recent months.

Credit: Source link

ShareTweetSendSharePin

Related Posts

Trump’s tariff craze has derailed the GOP’s hopes to maintain their authority after the 2026 midterms
Business

Trump’s tariff craze has derailed the GOP’s hopes to maintain their authority after the 2026 midterms

November 1, 2026
West Coast favorite ice cream chain opens new Bay Area store
Business

West Coast favorite ice cream chain opens new Bay Area store

November 1, 2026
Ray-Ban heir recounts wild pregnancy mystery with ex Jessica Serfaty: ‘I’m pregnant — It can be you or him’
Business

Ray-Ban heir recounts wild pregnancy mystery with ex Jessica Serfaty: ‘I’m pregnant — It can be you or him’

October 31, 2026
McDonald’s dealt legal setback as judge allows lawsuit over McRib’s ‘lack of rib meat’ to proceed
Business

McDonald’s dealt legal setback as judge allows lawsuit over McRib’s ‘lack of rib meat’ to proceed

October 31, 2026
Next Post
Exa AI Introduces Exa Instant: A Sub-200ms Neural Search Engine Designed to Eliminate Bottlenecks for Real-Time Agentic Workflows

Exa AI Introduces Exa Instant: A Sub-200ms Neural Search Engine Designed to Eliminate Bottlenecks for Real-Time Agentic Workflows

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
BTS fans form kilometer-long queues for Peru debut show

BTS fans form kilometer-long queues for Peru debut show

October 29, 2026
AMDY: The Payout Is Shrinking Even With AMD Near Highs (NYSEARCA:AMDY)

AMDY: The Payout Is Shrinking Even With AMD Near Highs (NYSEARCA:AMDY)

October 27, 2026
Credo Is Still Not Worth Buying Again

Credo Is Still Not Worth Buying Again

October 28, 2026

About

Learn more

Our Services

Legal

Privacy Policy

Terms of Use

Bloggers

Learn more

Article Links

Contact

Advertise

Ask us anything

©2020- TradePoint.io - All rights reserved!

Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.

This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.

No Result
View All Result
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop

© 2023 - TradePoint.io - All Rights Reserved!